BupiZenge™
Oral Mucositis Pain
Phase 3 PlanningActive
Key Facts
About OncoZenge
OncoZenge is a clinical-stage biotech developing BupiZenge™, a novel lozenge formulation of the anesthetic bupivacaine for the localized treatment of oral mucositis pain. The product has successfully completed Phase 1 and 2 trials and has received regulatory guidance from the FDA and EMA, with Phase 3 planning underway. The company is targeting a large global market with no approved therapeutic treatments, positioning BupiZenge™ as a potential first-in-class, non-opioid solution that could significantly improve patient quality of life and reduce systemic opioid use.
View full company profile